Here, the neoplasm condition must be reported as an additional code
Patients and providers still sought these therapies, but without a legal, regulated option, a gray market began to fill the gap, one characterized by unverified sources, inconsistent quality, and little to no pharmacist oversight.[5] In that environment, the very risks regulators aim to mitigate can become more difficult to control
As of mid-2026, neither cagrilintide nor retatrutide is FDA- or EMA-approved for any indication, and no legitimate prescription product exists for either
Even with steady progress, some areas may look loose because the supporting structures beneath the skin have changed, and some people report facial skin that appears more aged after weight loss
Many peptides discussed here are not FDA-approved drugs